The concept of antigen specific TCR transduced lymphocytes for adoptive immunotherapy is gaining increasing support. For this to become a reality, however, the biology and in vivo response of these cells to the host environment, including tolerance, antigen presentation, and tumor microenvironment will have to be carefully delineated. Our translational research group recently has developed a series of novel observations/reagents to address this issue. First, we have observed that cyclophosphamide (CTX) preconditioning induces post-lymphopenia expansion of DC in the PBL. Second, we have delineated that IL- 12 conditioning during in vitro priming is able to promote the acquisition of an early effector (TEA) like phenotype. Both are associated with enhanced anti-tumor responses in vivo. Third, our program collaborator (Dr. Shikar Mehrotra) has successfully created a TCR transgenic mouse (termed h3T) which expresses functional melanoma antigen (tyrosinase) specific human TCR in peripheral CD8+ T cells thus providing a source of naive endogenous T cells expressing tyrosinase specific TCR and TCR transduced T cells of the same specificity. We hypothesize that combining the antigen specific response of TCR transduced CD8+ T cells with an environment which promotes DC function will result in the generation of more effective anti-tumor immunity. Therefore, we propose the following:
Specific Aim 1 will define the impact of homeostatic proliferation and mechanisms of IL-12 conditioning on TCR transduced T cell survival and function in a tumor bearing host. We will then assess the mechanisms by which IL-12 conditioning impacts on TCR transduced and h3T transgenic T cell survival looking specifically at CTLA-4, PD-1 signaling.
Specific Aim 2 will define the TCR transduced CD8+ T cell response to antigen presentation in an environment which promotes DC function evaluating both the post-lymphopenia expansion of DC environment, and also with a limited lymphopenia post CD8+ antibody depletion. PBL from the phase I clinical trial will be used to confirm our preclinical data for both aims. Finally, Specific Aim 3 will determine the optimal conditions required to induce a robust memory TCR transduced CD8+ T cell response in a tumor bearing environment evaluating the mechanisms affecting in vivo TCR transduced CD8+ T cells responses We will then define the therapeutic efficacy of TCR transduced T-cells adoptively transferred into a tumor bearing mouse. Using these novel tools to probe the mechanisms involved in the in vivo response of TCR transduced T cells to the host environment should provide an ability to design more effective adoptive immunotherapy protocols.
We have shown that eliminating the white blood cells in a tumor bearing mouse leads to a rapid repopulation of dendritic cells capable of activating and enhancing the function of adoptively transferred T cells. In this Project, we will examine the effect of these dendritic cells on TCR transduced T cells.
|Foley, Kendra C; Nishimura, Michael I; Moore, Tamson V (2018) Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. Melanoma Res 28:171-184|
|Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara et al. (2018) Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res :|
|Moore, Tamson; Wagner, Courtney Regan; Scurti, Gina M et al. (2018) Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunol Immunother 67:311-325|
|Johnson, C Bryce; May, Bennett R; Riesenberg, Brian P et al. (2018) Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res 78:3067-3074|
|Spear, Timothy T; Wang, Yuan; Smith Jr, Thomas W et al. (2018) Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. Mol Ther 26:996-1007|
|Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704|
|Spear, Timothy T; Foley, Kendra C; Garrett-Mayer, Elizabeth et al. (2018) TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. J Leukoc Biol 103:973-983|
|Riley, Timothy P; Hellman, Lance M; Gee, Marvin H et al. (2018) T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability. Nat Chem Biol 14:934-942|
|Nelson, Alexander; Cunha, Christina; Nishimura, Michael I et al. (2018) Activated human Foxp3+ regulatory T cells produce membrane-bound TNF. Cytokine 111:454-459|
|Knochelmann, Hannah M; Smith, Aubrey S; Dwyer, Connor J et al. (2018) CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front Immunol 9:1740|
Showing the most recent 10 out of 50 publications